Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement
Post buyback public announcement15-03-2024
15-03-2024
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of certificate / duplicate shares14-03-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials.14-03-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial.14-03-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus launches IBYRA, the generic version of Olaparib, brings both access and affordability for cancer patients in India.13-03-2024
Zydus Lifesciences Ltd - 532321 - Demand Order Received From Excise And Taxation Officer-Cum-State Tax Officer, Punjab
Demand order received from Excise and Taxation Officer-cum-State Tax Officer, Punjab12-03-2024
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Certificate / Duplicate Shares12-03-2024
Zydus Lifesciences Ltd - 532321 - Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Zydus receives EIR for the API Ahmedabad facility10-03-2024
Zydus Lifesciences Ltd - 532321 - Update
Zydus receives Post Application Action Letter for the USFDA cGMP and Pre-Approval Inspection (PAI) at the Ahmedabad API facility07-03-2024
Cadila Pharma Introduces Vaccine For Seasonal Flu
Cadila Pharmaceuticals on Monday said it has launched a vaccine to prevent influenza, a recurrent and widespread viral infection. The drug firm has introduced quadrivalent Cadiflu Tetra vaccine which has been approved by the DCGI (Drugs Controller General of India) for use in adults and children. The new vaccine targets four strains of the influenza virus subtype A and B, responsible for seasonal epidemics, the drug firm said in a statement.04-03-2024